MP
DALS

Mangrove Partners’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Mangrove Partners’s Portfolio DALS Stock Details DALS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-450,000
Closed -$4.5M – 352
2022
Q4 		$4.5M Hold
450,000
– – 0.25% 143
2022
Q3 		$4.38M Buy
450,000
+376,644
+513% +$3.66M 0.25% 158
2022
Q2 		$711K Buy
+73,356
New +$714K 0.03% 411

Other funds holding DALS

FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Mangrove Partners's DALS Position: Q1 2023 in Review

Mangrove Partners sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q1 2023, closing a stake of 450,000 shares — an estimated $4.5M sold.

Mangrove Partners first reported a position in DALS in Q2 2022 and held it in 3 quarters. The position peaked at $4.5M in Q4 2022. 50 funds tracked by Wall St. Rank hold DALS as of Q1 2023.

  • Mangrove Partners reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • Mangrove Partners sold 450,000 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q1 2023, an estimated $4.5M.
  • Mangrove Partners first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q2 2022 and held it in 3 quarters.
  • Mangrove Partners's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $4.5M in Q4 2022.
  • 50 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q1 2023.

Based on Mangrove Partners's 13F filing for Q1 2023, filed 15 May 2023.